RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

Core Insights - Bayer has announced results from the QUANTI Pediatric study, which provides additional pharmacokinetic, safety, and efficacy data for the investigational low-dose MRI gadolinium-based contrast agent gadoquatrane [1] Group 1: Study Overview - The QUANTI Pediatric study evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced MRI [1] - The study utilized a gadolinium dose of 0.04 mmol Gd/kg body weight, indicating a significant dose reduction compared to standard doses [1]